Charles River Laboratories

Charles River Laboratories

CRL · NYSE · Healthcare / Diagnostics & Research

337.97USD-2.84 (-0.83%)

Price History

Full chart

Market Stats

Previous Close340.81
Open342.18
Day Range333.04 – 342.58
52-Week Range145.47 – 303.31
Volume838.30K
Market Cap14.11B
P/E (TTM)0.00
Forward P/E22.42
EPS-4.80
Dividend Yield0.00%
Beta1.41
50-Day Avg267.77
200-Day Avg206.96

About

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and de

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMs. Birgit Girshick
  • Employees18.30K
  • Headquarters251 Ballardvale Street, Wilmington, MA, United States, 01887, USA
  • Websitehttps://www.criver.com

Leadership

  • Ms. Birgit GirshickCEO & Director · b. 1970
  • Mr. Michael Gunnar KnellCorporate Senior VP & Chief Accounting Officer · b. 1977
  • Mr. Joseph W. LaPlume J.D.Corporate Executive Vice President of Corporate Development & Strategy · b. 1974
  • Ms. Victoria L. CreamerCorporate Executive VP & Chief People Officer · b. 1970
  • Mr. Glenn G. Coleman CPACorporate Executive VP & CFO · b. 1968
  • Mr. Mark MintzCorporate EVP, Chief Information Officer & Global Shared Services · b. 1974
  • Mr. Todd SpencerCorporate Vice President of Investor Relations
  • Ms. Kerry DaileyCorporate Senior VP & Chief Legal Officer
  • Ms. Amy E. CianciarusoCorporate Senior Vice President, Chief Communications Officer & Government Relations
  • Dr. Brian F. Bathgate Ph.D.Corporate Senior Vice President of European Safety Assessment · b. 1960

Financials

Income Statement

Currency: USD1998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue193.30M219.28M306.58M465.63M554.63M613.72M766.92M1.12B1.06B1.23B1.34B1.20B1.13B1.14B1.13B1.17B1.30B1.36B1.68B1.86B2.27B2.62B2.92B3.54B3.98B4.13B4.05B4.02B
Growth (%)-+13.44%+39.82%+51.88%+19.11%+10.65%+24.96%+46.33%-5.69%+16.27%+9.17%-10.49%-5.75%+0.81%-1.15%+3.19%+11.34%+5.06%+23.34%+10.48%+21.99%+15.67%+11.55%+21.08%+12.31%+3.86%-1.92%-0.85%
Cost of Revenue122.55M146.73M186.65M298.38M345.65M380.06M435.50M603.62M651.78M752.43M832.78M748.65M748.66M740.40M737.45M770.63M825.00M832.21M1.04B1.16B1.43B1.66B1.85B2.21B2.51B2.63B2.72B2.79B
Gross Profit70.75M84.68M119.93M167.25M208.98M233.66M288.72M389.70M406.61M478.19M510.71M422.99M384.76M402.24M392.08M394.90M472.66M531.09M643.96M700.92M840.07M958.31M1.07B1.33B1.46B1.50B1.33B1.23B
Gross Margin36.60%38.62%39.12%35.92%37.68%38.07%37.65%34.73%38.42%38.86%38.01%35.17%33.95%35.20%34.71%33.88%36.42%38.96%38.30%37.73%37.07%36.56%36.72%37.70%36.79%36.39%32.88%30.52%
Operating Expense35.43M41.72M54.87M76.97M86.72M95.11M130.74M205.01M218.43M251.00M960.47M253.38M683.27M227.94M226.32M243.50M294.99M324.64M406.41M412.64M508.68M607.16M640.81M744.78M811.68M885.29M1.10B717.73M
Operating Income35.33M42.96M65.06M90.28M122.27M138.55M157.99M184.69M188.17M227.19M-449.76M169.61M-298.51M174.31M165.76M151.40M177.67M206.45M237.55M288.28M331.38M351.15M432.73M589.86M650.98M617.26M227.35M507.84M
Operating Margin18.27%19.59%21.22%19.39%22.04%22.58%20.60%16.46%17.78%18.46%-33.48%14.10%-26.34%15.25%14.68%12.99%13.69%15.14%14.13%15.52%14.62%13.40%14.80%16.66%16.37%14.95%5.61%12.65%
EBITDA46.22M58.61M83.93M118.86M147.99M169.67M201.92M274.81M273.30M321.81M-355.82M263.20M-205.15M260.48M244.36M255.93M285.99M305.38M377.29M457.89M507.23M563.06M768.47M820.16M986.15M1.03B581.14M410.84M
EBITDA Margin23.91%26.73%27.38%25.53%26.68%27.65%26.33%24.49%25.82%26.15%-26.48%21.89%-18.10%22.80%21.63%21.96%22.04%22.40%22.44%24.65%22.38%21.48%26.28%23.17%24.80%24.99%14.35%10.23%
Net Income23.38M17.12M-11.22M35.41M50.13M80.15M89.79M142.00M-55.78M154.41M-521.84M114.44M-336.67M109.57M97.30M102.83M126.70M149.31M154.76M123.36M226.37M252.02M364.30M390.98M486.23M474.62M10.30M-144.34M
Net Income Margin12.09%7.81%-3.66%7.60%9.04%13.06%11.71%12.65%-5.27%12.55%-38.84%9.52%-29.70%9.59%8.61%8.82%9.76%10.95%9.20%6.64%9.99%9.61%12.46%11.04%12.23%11.49%0.25%-3.59%
R&D------------000000000-------
R&D as % of Total Revenue------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-------
Interest Expense2.12M8.28M67.35M27.28M27.34M6.56M8.65M22.62M193.24M14.83M14.01M21.68M34.09M41.23M33.34M20.97M11.95M15.07M27.71M29.78M63.77M60.88M86.43M73.91M59.29M136.71M126.29M107.03M
Interest Expense % of Total Revenue1.10%3.78%21.97%5.86%4.93%1.07%1.13%2.02%18.26%1.21%1.04%1.80%3.01%3.61%2.95%1.80%0.92%1.11%1.65%1.60%2.81%2.32%2.96%2.09%1.49%3.31%3.12%2.67%

Balance Sheet

Currency: USD1998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets234.25M363.06M410.61M571.36M701.34M799.55M2.63B2.54B2.56B2.81B2.16B2.20B1.73B1.56B1.59B1.64B1.89B2.07B2.71B2.93B3.86B4.69B5.49B7.02B7.60B8.20B7.53B7.14B
Total Liabilities65.69M472.89M280.35M268.86M325.40M324.75M1.14B701.48M953.11M941.57M960.47M830.27M1.04B1.03B983.14M979.96M1.18B1.30B1.86B1.87B2.52B3.03B3.35B4.43B4.58B4.54B4.02B3.92B
Total Equity168.26M-110.14M116.93M289.51M357.38M464.62M1.47B1.83B1.60B1.86B1.20B1.37B687.42M527.36M600.80M640.98M672.20M733.07M836.77M1.05B1.32B1.63B2.11B2.53B2.98B3.60B3.46B3.16B
Cash24.81M15.01M33.13M58.27M122.51M182.33M207.57M114.82M175.38M225.45M243.59M182.57M179.16M68.91M109.69M155.93M160.02M117.95M117.63M163.79M195.44M238.01M228.42M245.24M233.91M276.77M194.61M213.77M
Total Debt1.58M386.04M202.91M156.80M192.48M185.68M686.85M296.66M572.06M510.05M576.10M492.83M700.85M717.95M666.52M663.79M777.86M863.03M1.24B1.15B1.70B2.02B2.16B3.21B3.10B3.07B2.72B3.07B
Net Debt-23.23M371.03M169.78M98.53M69.97M3.35M479.28M181.84M396.68M284.60M332.51M310.26M521.69M649.04M556.84M507.86M617.84M745.08M1.12B981.31M1.50B1.79B1.93B2.96B2.86B2.79B2.53B2.85B

Cash Flow

Currency: USD1998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow37.38M37.57M33.77M71.30M133.66M123.77M184.83M236.70M164.37M284.25M279.95M225.04M169.01M205.28M207.90M207.14M251.05M286.36M298.32M316.26M441.14M480.94M546.58M760.80M619.64M683.90M734.58M737.65M
Investing Cash Flow-23.03M-34.17M-14.58M-91.92M-78.89M-63.39M-599.97M-113.99M-107.99M-200.78M-227.18M-208.82M5.76M-36.65M-54.99M-74.05M-297.99M-320.29M-686.37M-72.59M-955.00M-681.50M-601.54M-1.44B-607.92M-563.15M-245.09M-209.32M
Financing Cash Flow-8.02M-11.50M782.00K47.23M5.17M-8.79M436.95M-197.58M5.39M-46.43M-17.32M-80.98M-167.90M-271.79M-111.12M-84.24M61.41M4.55M390.73M-208.48M558.06M231.94M47.25M672.60M-42.40M-85.52M-550.93M-536.73M
Capital Expenditure11.91M12.95M15.56M36.66M37.54M32.70M45.34M95.55M181.75M227.04M197.08M80.01M42.86M49.14M47.53M39.15M56.92M63.25M55.29M82.43M140.05M140.51M166.56M228.77M324.73M318.53M232.97M219.15M
Free Cash Flow25.47M24.62M18.20M34.64M96.12M91.06M139.49M141.15M-17.38M57.21M82.87M145.03M126.15M156.14M160.37M167.99M194.13M223.11M243.03M233.83M301.09M340.42M380.01M532.03M294.91M365.37M501.61M518.49M
Dividends Paid---729.00K1.47M1.90M2.11M1.40M1.92M1.92M--00000000-34.55M46.59M45.65M-25.60M--
FCF to OCF68.14%65.53%53.91%48.59%71.91%73.58%75.47%59.63%-10.57%20.13%29.60%64.45%74.64%76.06%77.14%81.10%77.33%77.91%81.47%73.94%68.25%70.78%69.53%69.93%47.59%53.42%68.29%70.29%
Dividend Paid to FCF---2.10%1.53%2.09%1.51%0.99%-11.03%3.35%--0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-10.15%12.26%8.58%-7.01%--

Earnings

Report DateAug 2, 2000Nov 1, 2000Feb 14, 2001May 4, 2001Aug 2, 2001Oct 31, 2001Feb 6, 2002May 1, 2002Jul 30, 2002Oct 29, 2002Feb 3, 2003Apr 30, 2003Jul 29, 2003Oct 29, 2003Feb 10, 2004Apr 28, 2004Jul 28, 2004Oct 28, 2004Feb 14, 2005May 3, 2005Jul 28, 2005Oct 27, 2005Feb 8, 2006May 9, 2006Aug 8, 2006Nov 6, 2006Feb 12, 2007May 8, 2007Aug 7, 2007Nov 5, 2007Feb 11, 2008May 6, 2008Aug 5, 2008Nov 5, 2008Feb 9, 2009May 5, 2009Aug 4, 2009Nov 3, 2009Feb 8, 2010Apr 26, 2010Aug 2, 2010Nov 3, 2010Feb 8, 2011May 3, 2011Aug 2, 2011Nov 1, 2011Feb 13, 2012May 2, 2012Aug 7, 2012Oct 30, 2012Feb 13, 2013May 1, 2013Jul 31, 2013Oct 29, 2013Feb 11, 2014Apr 30, 2014Aug 6, 2014Oct 29, 2014Feb 10, 2015Apr 29, 2015Jul 30, 2015Nov 4, 2015Feb 10, 2016May 4, 2016Aug 3, 2016Nov 2, 2016Feb 14, 2017May 10, 2017Aug 9, 2017Nov 9, 2017Feb 13, 2018May 10, 2018Aug 8, 2018Nov 7, 2018Feb 13, 2019May 7, 2019Jul 31, 2019Nov 6, 2019Feb 11, 2020May 7, 2020Aug 5, 2020Oct 29, 2020Feb 17, 2021May 4, 2021Aug 4, 2021Nov 3, 2021Feb 16, 2022May 4, 2022Aug 3, 2022Nov 2, 2022Feb 22, 2023May 11, 2023Aug 9, 2023Nov 8, 2023Feb 14, 2024May 9, 2024Aug 7, 2024Nov 6, 2024Feb 19, 2025May 7, 2025Aug 6, 2025Nov 5, 2025Feb 18, 2026May 7, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate0.080.080.090.170.210.240.240.270.320.360.360.400.410.400.380.440.500.490.470.550.600.570.570.560.530.540.580.610.620.620.630.680.730.750.550.530.580.600.440.470.480.490.490.540.600.580.550.650.660.620.600.710.710.700.680.740.820.800.710.820.970.940.940.901.101.131.111.141.221.221.251.261.461.381.401.391.551.641.831.461.281.802.112.192.382.582.432.722.742.502.752.592.642.372.402.062.392.422.532.072.552.322.331.952.722.96
EPS Actual0.180.120.110.190.240.260.240.310.360.390.360.410.430.400.420.470.520.510.480.550.590.570.590.500.570.560.580.640.640.680.650.720.790.760.590.580.660.650.490.450.430.450.600.610.700.570.690.700.750.650.640.690.730.790.730.820.970.860.810.790.961.031.000.981.201.181.211.291.291.301.401.381.621.531.491.401.631.692.011.841.582.332.392.532.612.702.492.752.772.632.982.782.692.722.462.272.802.592.662.343.122.432.392.063.02-
Surprise125.00%50.00%22.22%11.76%14.29%8.33%0.00%14.81%12.50%8.33%0.00%2.50%4.88%0.00%10.53%6.82%4.00%4.08%2.13%0.00%-1.67%0.00%3.51%-10.71%7.55%3.70%0.00%4.92%3.23%9.68%3.17%5.88%8.22%1.33%7.27%9.43%13.79%8.33%11.36%-4.26%-10.42%-8.16%22.45%12.96%16.67%-1.72%25.45%7.69%13.64%4.84%6.67%-2.82%2.82%12.86%7.35%10.81%18.29%7.50%14.08%-3.66%-1.03%9.57%6.38%8.89%9.09%4.42%9.01%13.16%5.74%6.56%12.00%9.52%10.96%10.87%6.43%0.72%5.16%3.05%9.84%26.03%23.44%29.44%13.27%15.53%9.66%4.65%2.47%1.10%1.09%5.20%8.36%7.34%1.89%14.77%2.50%10.19%17.15%7.02%5.14%13.04%22.35%4.74%2.58%5.64%11.03%-
Timing-----After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap14.11B
Enterprise Value16.08B
Trailing P/E0.00
Forward P/E22.42
PEG Ratio0.12
Price / Sales3.50
Price / Book4.66
EPS-4.80
Book Value59.50
Revenue (TTM)4.00B
Gross Profit (TTM)1.38B
EBITDA849.12M
Profit Margin-5.96%
Operating Margin15.11%
Return on Equity-7.52%
Return on Assets4.11%
Shares Outstanding48.17M
Shares Float47.22M
Beta1.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 19 analystsTarget 296.64
  • Strong Buy
    4
  • Hold
    14
  • Strong Sell
    1

Ownership Breakdown

Institutions
123.67%
Insiders
0.47%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    3.86M8.08%
  • FMR Inc
    3.46M7.24%
  • Vanguard Capital Management, LLC
    3.20M6.71%
  • Amvescap Plc.
    2.40M5.02%
  • Vanguard Portfolio Management, LLC
    2.29M4.81%
  • Harris Associates L.P.
    2.24M4.69%
  • Allspring Global Investments Holdings, LLC
    1.91M3.99%
  • State Street Corp
    1.87M3.92%
  • Dimensional Fund Advisors, Inc.
    1.65M3.45%
  • Ariel Investments, LLC
    1.51M3.15%
  • Geode Capital Management, LLC
    1.31M2.74%
  • Wellington Management Company LLP
    1.29M2.70%
  • Citadel Advisors Llc
    1.19M2.50%
  • Bank of America Corp
    1.14M2.38%
  • T. Rowe Price Associates, Inc.
    1.13M2.36%
  • Ameriprise Financial Inc
    1.11M2.32%

Top Fund Holders

  • Fidelity Contrafund
    1.83M3.82%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.53M3.21%
  • Oakmark Select Investor
    1.50M3.14%
  • Vanguard 500 Index Investor
    1.28M2.68%